智通财经APP获悉,KalVista制药公司(KALV.US)宣布,其治疗遗传性血管性水肿的口服药物已获得美国食品药品监督管理局(FDA)批准。遗传性血管性水肿是一种罕见且可能致命的疾病,会导致全身严重肿胀。截至发稿,该股在美东时间周一盘前上涨18%。上月,FDA曾告知KalVista无法在6月的审批截止日前做出决定。该公司当时表示,监管机构称因“工作量大、资源有限”而推迟决策。近期政府机构裁员...
Source Link智通财经APP获悉,KalVista制药公司(KALV.US)宣布,其治疗遗传性血管性水肿的口服药物已获得美国食品药品监督管理局(FDA)批准。遗传性血管性水肿是一种罕见且可能致命的疾病,会导致全身严重肿胀。截至发稿,该股在美东时间周一盘前上涨18%。上月,FDA曾告知KalVista无法在6月的审批截止日前做出决定。该公司当时表示,监管机构称因“工作量大、资源有限”而推迟决策。近期政府机构裁员...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.